Morgan Stanley Health Sciences I
522 Fifth Avenue Jersey City NJ 07311
Map
Phone: 800-869-6397
| Category: | Health | | Fund Family: | Morgan Stanley | | Net Assets: | 330.00K | | Year-to-Date Return: | 10.00% | | Yield: | 0.00% | | Morningstar Rating: |  | | Fund Inception Date: | 28-Jul-97 |
|
Michael Nolan
Lead Manager since
30-Jun-08 | | | Nolan has been associated with the Investment Adviser in an investment management capacity since November 2005. Prior to November 2005, he was responsible for Morgan Stanley & Company?s collateralized debt obligation business in Europe. |
| Min Initial Investment: | $5,000,000 | | Min Initial Investment, IRA: | NaN | | Min Initial Investment, AIP: | NaN | | Min Subsequent Investment: | NaN | | Min Subsequent Investment, IRA: | N/A | | Min Subsequent Investment, AIP: | N/A |
|
| |
| The investment seeks capital appreciation. The fund normally invests at least 80% of assets in common stocks (including depositary receipts) of health science companies throughout the world. It may invest up to 50% of net assets in foreign securities, including emerging-market securities. The fund may invest the remaining 20% of assets in the common stock of non-health science companies, preferred stock and investment-grade fixed-income securities. |
| Last Dividend
| YFT_NOT_APPLICABLE_ABBREVIATION | | Last Cap Gain
(15-Dec-08):
| 0.45 | | Annual Holdings Turnover
| YFT_NOT_APPLICABLE_ABBREVIATION | | Average for Category:
| 109.30% |
|
| Expense | HCRDX | Category
Avg | | Total Expense Ratio: | 1.25%
| 1.67% | | Max 12b1 Fee: | %
| N/A | | Max Front End Sales Load: | %
| 5.35% | | Max Deferred Sales Load: | %
| 2.88% | | 3 Yr Expense Projection*: |
$ 397 | $716 | | 5 Yr Expense Projection*: |
$ 686 | $1,069 | | 10 Yr Expense Projection*: |
$ 1,511 | $2,090 |
|
|
2.03% Nasdaq 
Profile
